Psoriatic arthritis: treatment strategies using biologic agents

被引：15

作者：

D'Angelo, S. ^{[1
,2
]}

Palazzi, C. ^{[1
,2
]}

Olivieri, I. ^{[1
,2
]}

机构：

[1] San Carlo Hosp Potenza, Rheumatol Dept Lucania, I-85100 Potenza, Italy

[2] Madonna Grazie Hosp Matera, Potenza, Italy

来源：

REUMATISMO | 2012年 / 64卷 / 02期

关键词：

Psoriatic disease; psoriatic arthritis; therapy; biologic drugs; anti-TNF alpha agents;

D O I：

10.4081/reumatismo.2012.113

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The traditional management of psoriatic arthritis (PsA) includes NSAIDs, corticosteroids and DMARDs. Advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents which have revolutionized the management of the disease. Among biologics drugs, there are the 4 currently available anti-TNF alpha blocking agents (etanercept, infliximab, adalimumab and golimumab) which are more effective than traditional DMARDs on symptoms/signs of inflammation, quality of life, function, and in inhibiting the progression of the structural joint damage. Despite of the high cost, TNF inhibitors are costeffective on both the musculoskeletal and skin manifestations of psoriatic disease.

引用

页码：113 / 121

页数：9

共 53 条

[31] Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial [J].

Mease, PJ ;

Gladman, DD ;

Ritchlin, CT ;

Ruderman, EM ;

Steinfeld, SD ;

Choy, EHS ;

Sharp, JT ;

Ory, PA ;

Perdok, RJ ;

Weinberg, MA .

ARTHRITIS AND RHEUMATISM, 2005, 52 (10) :3279-3289

[32] The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy [J].

Olivieri, I. ;

de Portu, S. ;

Salvarani, C. ;

Cauli, A. ;

Lubrano, E. ;

Spadaro, A. ;

Cantini, F. ;

Cutro, M. S. ;

Mathieu, A. ;

Matucci-Cerinic, M. ;

Pappone, N. ;

Punzi, L. ;

Scarpa, R. ;

Mantovani, L. G. .

RHEUMATOLOGY, 2008, 47 (11) :1664-1670

[33]

Olivieri I, 2012, J RHEUMATOL IN PRESS

[34]

Olivieri I, 2008, J RHEUMATOL, V35, P3

[35] Emerging drugs for psoriatic arthritis [J].

Olivieri, Ignazio ;

D'Angelo, Salvatore ;

Palazzi, Carlo ;

Lubrano, Ennio ;

Leccese, Pietro .

EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (03) :399-414

[36]

Olivieri I, 2009, EXPERT OPIN PHARMACO, V10, P271, DOI [10.1517/14656560802653198, 10.1517/14656560802653198 ]

[37]

Palazzi C, 2011, CLIN EXP RHEUMATOL, V29, P858

[38] Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease [J].

Punzi, L ;

Pianon, M ;

Rossini, P ;

Schiavon, F ;

Gambari, PF .

ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (04) :226-229

[39] Treatment recommendations for psoriatic arthritis [J].

Ritchlin, C. T. ;

Kavanaugh, A. ;

Gladman, D. D. ;

Mease, P. J. ;

Helliwell, P. ;

Boehncke, W-H ;

de Vlam, K. ;

Fiorentino, D. ;

FitzGerald, O. ;

Gottlieb, A. B. ;

McHugh, N. J. ;

Nash, P. ;

Qureshi, A. A. ;

Soriano, E. R. ;

Taylor, W. J. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (09) :1387-1394

[40]

Rodgers M, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI [10.3310/hta15suppl1/01, 10.3310/hta15100]

← 1 2 3 4 5 6 →